Cargando…
Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer
Neuroendocrine prostate cancer (NEPC) is the most lethal malignancy of prostate cancer (PCa). Treatment with next-generation androgen receptor (AR) pathway inhibitors (ARPIs) has successfully extended patients' lifespan. However, with the emergence of drug resistance, PCa tumors increasingly ad...
Autores principales: | Cheng, Wen-Chi, Wang, Hung-Jung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323647/ https://www.ncbi.nlm.nih.gov/pubmed/34386358 http://dx.doi.org/10.4103/tcmj.tcmj_220_20 |
Ejemplares similares
-
Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment
por: Zhang, Shouyi, et al.
Publicado: (2023) -
The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer
por: Singh, Prashant Kumar, et al.
Publicado: (2013) -
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
por: Cejas, Paloma, et al.
Publicado: (2021) -
Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy
por: Jung, Inkyung, et al.
Publicado: (2023) -
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer
por: Zamora, Irene, et al.
Publicado: (2023)